Amneal Pharmaceuticals (AMRX) Operating Leases (2019 - 2026)
Amneal Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $58.8 million for Q4 2025.
- For Q4 2025, Operating Leases rose 25.01% year-over-year to $58.8 million; the TTM value through Dec 2025 reached $58.8 million, up 25.01%, while the annual FY2025 figure was $58.8 million, 25.01% up from the prior year.
- Operating Leases for Q4 2025 was $58.8 million at Amneal Pharmaceuticals, up from $26.4 million in the prior quarter.
- Over five years, Operating Leases peaked at $64.0 million in Q4 2021 and troughed at $11.1 million in Q2 2024.
- A 5-year average of $29.8 million and a median of $26.3 million in 2022 define the central range for Operating Leases.
- Biggest five-year swings in Operating Leases: plummeted 48.43% in 2023 and later surged 92.75% in 2024.
- Year by year, Operating Leases stood at $64.0 million in 2021, then dropped by 7.45% to $59.2 million in 2022, then fell by 17.42% to $48.9 million in 2023, then fell by 3.84% to $47.0 million in 2024, then grew by 25.01% to $58.8 million in 2025.
- Business Quant data shows Operating Leases for AMRX at $58.8 million in Q4 2025, $26.4 million in Q3 2025, and $16.4 million in Q2 2025.